share_log

MSCI Inc | 8-K: Current report

MSCI Inc | 8-K: Current report

MSCI Inc | 8-K:重大事件
美股SEC公告 ·  2024/08/01 18:51

牛牛AI助理已提取核心訊息

MSCI announced the appointment of Michelle Seitz as an independent director to its Board of Directors, effective August 5, 2024. Seitz will serve on the Board's Audit and Risk Committee, bringing the total board membership to 12 directors. As per the non-employee director compensation program, she will receive an annual retainer of $90,000 and restricted stock units worth $210,000, plus an additional $10,000 for committee service.Seitz brings extensive investment industry experience as the current Founder and CEO of MeydenVest Partners and former Chair and CEO of Russell Investments (2017-2022). Her prior experience includes leadership roles at William Blair, where she served as CEO of William Blair Investment Management and drove fivefold growth. She currently serves on the board of Sana Biotechnology and holds a CFA designation.The appointment follows an extensive search initiated last year, with MSCI Chairman and CEO Henry Fernandez highlighting Seitz's three decades of asset management experience and track record in driving transformational growth. The Board has confirmed her independence under both NYSE and SEC standards.
MSCI announced the appointment of Michelle Seitz as an independent director to its Board of Directors, effective August 5, 2024. Seitz will serve on the Board's Audit and Risk Committee, bringing the total board membership to 12 directors. As per the non-employee director compensation program, she will receive an annual retainer of $90,000 and restricted stock units worth $210,000, plus an additional $10,000 for committee service.Seitz brings extensive investment industry experience as the current Founder and CEO of MeydenVest Partners and former Chair and CEO of Russell Investments (2017-2022). Her prior experience includes leadership roles at William Blair, where she served as CEO of William Blair Investment Management and drove fivefold growth. She currently serves on the board of Sana Biotechnology and holds a CFA designation.The appointment follows an extensive search initiated last year, with MSCI Chairman and CEO Henry Fernandez highlighting Seitz's three decades of asset management experience and track record in driving transformational growth. The Board has confirmed her independence under both NYSE and SEC standards.
MSCI宣佈聘任Michelle Seitz爲其董事會的獨立董事,自2024年8月5日起生效。Seitz將擔任董事會的審計和風險委員會成員,使董事會成員總數增至12位董事。根據非僱員董事薪酬計劃,她將獲得90,000美元的年薪和價值210,000美元的限制性股票單位,以及額外10,000美元的委員會服務費。Seitz在投資行業擁有豐富的經驗,目前是MeydenVest Partners的創始人兼首席執行官,曾擔任Russell Investments的董事會主席和首席執行官(2017-2022年)。她之前在William Blair擔任重要領導職務,曾擔任William Blair投資管理公司...展開全部
MSCI宣佈聘任Michelle Seitz爲其董事會的獨立董事,自2024年8月5日起生效。Seitz將擔任董事會的審計和風險委員會成員,使董事會成員總數增至12位董事。根據非僱員董事薪酬計劃,她將獲得90,000美元的年薪和價值210,000美元的限制性股票單位,以及額外10,000美元的委員會服務費。Seitz在投資行業擁有豐富的經驗,目前是MeydenVest Partners的創始人兼首席執行官,曾擔任Russell Investments的董事會主席和首席執行官(2017-2022年)。她之前在William Blair擔任重要領導職務,曾擔任William Blair投資管理公司的首席執行官,並推動了五倍的增長。她目前擔任Sana生物技術公司的董事,並持有CFA證書。此任命是在去年的廣泛搜索之後進行的,MSCI董事長兼首席執行官Henry Fernandez強調了Seitz在資產管理方面三十年的經驗以及她推動變革性增長的優秀記錄。董事會已根據紐交所和SEC標準確認了她的獨立性。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。